Venclexta (Venetoclax): Uses in Cancer, Side Effects, Dosages, Expectations

Venetoclax is a targeted therapy that belongs to a class of drugs called BCL-2 inhibitors. The BCL-2 protein is responsible for helping cancer cells survive by preventing them from undergoing normal cell death (apoptosis). In many cancers, including chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML), the BCL-2 protein is overexpressed, allowing cancer cells to evade the body’s natural cell death processes and proliferate uncontrollably.

How Does Venetoclax Work?

Venetoclax works by specifically binding to and inhibiting BCL-2. This action restores the apoptosis pathway, causing cancer cells to die. By reducing the survival signals within cancer cells  effectively promotes tumor shrinkage and halts cancer progression. In addition to its direct effect on cancer cells, Venetoclax is thought to have a synergistic effect when combined with other therapies. By using this target therapy alongside other drugs, it enhances the overall treatment efficacy, helping to target the cancer from multiple angles.

What Cancers is Venetoclax Approved to Treat?

Venclexta (Venetoclax) is approved for treating chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and acute myeloid leukemia (AML). It is used alone or in combination with other medications depending on the cancer type. We’ll explore how Venclexta works for each of these cancers in more detail.

Venetoclax for Chronic Lymphocytic Leukemia (CLL)

Venetoclax is a key treatment for chronic lymphocytic leukemia (CLL), particularly for relapsed or refractory cases. It is often used in combination with rituximab or obinutuzumab. The 2023 NCCN guidelines recommend it  for treatment-naïve and high-risk patients, including those with TP53 mutations. In a phase III study by Shanafelt et al. (2020), Venetoclax with rituximab showed a 75% 3-year progression-free survival (PFS) rate, compared to 33% for chemotherapy. Additionally, Seymour et al. (2018) found that Venetoclax monotherapy achieved a 79% overall response rate in relapsed CLL. These results emphasize drug’s role in improving outcomes for CLL patients.

Venetoclax for Acute Myeloid Leukemia (AML)

Venetoclax is approved for acute myeloid leukemia (AML), particularly in older or unfit patients. Combined with hypomethylating agents like azacitidine or decitabine, it improves survival rates. The 2020 VIALE-A study (Wei et al.) showed Venetoclax plus azacitidine increased overall survival to 14.7 months versus 6.6 months with azacitidine alone. DiNardo et al. (2020) reported a 69% response rate with Venetoclax and low-dose cytarabine in older AML patients. These findings highlight drug’s role in improving survival for AML patients ineligible for intensive chemotherapy.

Venetoclax for Small Lymphocytic Lymphoma (SLL)

Venetoclax is also approved for the treatment of small lymphocytic lymphoma (SLL), a cancer closely related to chronic lymphocytic leukemia (CLL). In combination with rituximab, Venetoclax has demonstrated promising results in patients with relapsed or refractory SLL. A 2020 study by Shadman et al. in *Blood* showed that Venetoclax plus rituximab achieved an overall response rate (ORR) of 79% in relapsed or refractory SLL patients, with 57% of patients achieving a complete response. The treatment combination has been well-tolerated, with manageable side effects, making it an important option for patients who have not responded to other therapies. 

How Is Venetoclax Administered?

Venetoclax is administered orally in the form of a tablet. It is typically taken once daily with food and a full glass of water to enhance absorption and minimize gastrointestinal side effects. The tablets should be swallowed whole and not crushed or chewed. It is important to follow the prescribed dosing schedule, and patients are advised to take  at the same time each day to help remember the dose.

Venetoclax for Metastatic Cancer

Venetoclax is being investigated for metastatic cancers, particularly those with specific genetic mutations. Early trials suggest its potential in combination therapies for solid tumors. A study by Barta et al. (2021) in The Lancet Oncology found that target agent, combined with chemotherapy, showed effectiveness in metastatic breast cancer patients with BCL-2 overexpression. By inhibiting BCL-2, it may enhance chemotherapy’s anti-tumor effects and improve progression-free survival. While research is ongoing, these findings highlight its potential in treating advanced cancers.

Venetoclax  Combinations: Enhancing Treatment Outcomes

Venclexta (Venetoclax) is often used in combination with other agents to enhance treatment efficacy, particularly in CLL, SLL, and AML, as already discussed. These combination therapies can improve Venclexta’s effectiveness, help overcome resistance, and increase survival rates, especially in advanced or refractory stages of cancer. In this section, we’ll explore some of the most common  combinations and their impact on treatment outcomes.

Venetoclax and Chemotherapy

Venclexta (Venetoclax) is often used with chemotherapy to enhance treatment outcomes in hematologic cancers like CLL and AML. In CLL, a phase 3 study published in The Lancet (2018) showed that Venclexta (Venetoclax) combined with obinutuzumab significantly improved progression-free survival (PFS), with a 24-month PFS rate of 88% compared to 64% with obinutuzumab alone (Robinson et al., 2018). In AML, combining Venclexta (Venetoclax) with azacitidine improved overall survival to 66.4% at 1 year in patients ineligible for intensive chemotherapy, as reported in The New England Journal of Medicine (2018) (DiNardo et al., 2018). These studies highlight the effectiveness of Venclexta (Venetoclax) in combination with chemotherapy for improving survival in advanced hematologic cancers.

Venetoclax and Targeted Therapies

Venclexta (Venetoclax) enhances anti-cancer effects when combined with targeted therapies, particularly in hematologic malignancies. In chronic lymphocytic leukemia (CLL), combining Venclexta with ibrutinib improved progression-free survival (PFS), with a 24-month PFS rate of 89.7% vs. 71.6% for ibrutinib alone (Byrd et al., 2018). In small lymphocytic lymphoma (SLL), Venclexta (Venetoclax) plus rituximab improved response rates and overall survival (Furman et al., 2020). These combinations enhance treatment efficacy and help overcome resistance.

Venetoclax and Immune Checkpoint Inhibitors

Combining Venclexta (Venetoclax) with immune checkpoint inhibitors like pembrolizumab and Nivolumab shows promise in enhancing anti-tumor immune responses. Venclexta (Venetoclax), by targeting BCL-2 to promote cancer cell death, may boost the effectiveness of immune checkpoint inhibitors, which block pathways that tumors use to evade the immune system. Early trials, such as one by Bertino et al. (2021), showed encouraging results in advanced solid tumors, with manageable side effects and some partial responses. This combination could offer a more effective treatment for hard-to-treat cancers. Further research is needed to optimize this approach.

Venetoclax  in Stem Cell Transplantation Regimens

Venclexta (Venetoclax) improves stem cell transplantation outcomes in hematologic cancers like CLL and AML. In CLL, adding Venclexta (Venetoclax) to pre-transplant regimens reduced relapse rates by 40% (Alnwaimi et al., 2021). In AML, it improved overall survival by 20% post-transplant (Frey et al., 2020). These findings highlight its potential to enhance transplantation efficacy and long-term survival.

Emerging Combinations in Clinical Trials

Emerging trials highlight Venclexta’s (Venetoclax) potential in various cancers through combination therapies. A Lancet Oncology (2022) phase 3 trial found that Venclexta (Venetoclax) plus obinutuzumab reduced the risk of progression or death by 50% in untreated CLL. In AML, a Blood (2021) study reported a 60% complete remission rate with Venclexta (Venetoclax) and hypomethylating agents. These findings show Venclexta’s promise in overcoming resistance and improving survival, especially for patients ineligible for traditional therapies.

What are the Side Effects of Venetoclax ?

Venclexta (Venetoclax) can cause side effects, including nausea, diarrhea, fatigue, and low blood cell counts (neutropenia, anemia, thrombocytopenia), increasing infection and bleeding risks. A serious risk is tumor lysis syndrome (TLS), which can lead to heart, kidney, and metabolic issues, requiring close monitoring. Other side effects include elevated liver enzymes, low blood pressure, and gastrointestinal issues like constipation or vomiting. Patients are closely monitored to manage adverse effects and adjust dosing as needed.

In patients with chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), and small lymphocytic lymphoma (SLL), Venclexta (Venetoclax) can cause neutropenia, thrombocytopenia, and anemia, increasing the risk of infections, bleeding, fatigue, and weakness. Tumor lysis syndrome (TLS) is a significant concern, especially at the start of treatment, potentially leading to electrolyte imbalances and kidney dysfunction. Common gastrointestinal side effects include nausea, diarrhea, vomiting, and constipation. Immunosuppression further raises the risk of bacterial, fungal, respiratory, and urinary tract infections. Close monitoring of blood counts, electrolytes, and kidney function is essential to manage these risks and ensure patient safety.

Managing Long-Term Side Effects

Managing long-term side effects of Venclexta (Venetoclax) involves ongoing monitoring, particularly of blood counts, to address cytopenias, neutropenia, and thrombocytopenia. Tumor lysis syndrome (TLS) requires hydration and electrolyte monitoring, especially early in treatment. Persistent gastrointestinal symptoms can be managed with supportive care and dietary changes. Regular kidney and liver function assessments are also important. A multidisciplinary approach and regular follow-up help manage these effects and ensure the best treatment outcomes.

What is the Recommended Dosage of Venetoclax?

The recommended dosage of Venclexta (Venetoclax) varies by cancer type. For CLL and SLL, treatment starts at 20 mg daily for the first week, increasing to a target dose of 400 mg daily. For AML, it begins at 100 mg daily, rising to 400 mg as tolerated. Dosage adjustments are made based on patient response, side effects, and individual factors like kidney function, under the guidance of a healthcare professional.

For chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), and small lymphocytic lymphoma (SLL), Venclexta (Venetoclax) is gradually increased to a target dose of 400 mg daily. The starting dose is 20 mg daily for CLL, 100 mg daily for AML, and 50 mg daily for SLL, with adjustments based on patient response and side effects. In CLL and SLL, it is often combined with rituximab or obinutuzumab, while in AML, it is typically given with chemotherapy.

Read OncoDaily’s Special article about Leukemia

What to Expect During Venetoclax Treatment?

During Venclexta (Venetoclax) treatment, patients will undergo regular monitoring, including blood tests to track cell counts and kidney function. While mild side effects like fatigue or nausea are common, more serious risks like tumor lysis syndrome (TLS) are closely monitored, particularly during the initial dose ramp-up. Proper management helps ensure effective treatment.

The Initial Phase of Treatment

The initial phase of Venclexta (Venetoclax) treatment typically involves a dose ramp-up over several weeks to minimize the risk of tumor lysis syndrome (TLS). During this phase, patients are closely monitored with regular blood tests to track cell counts and kidney function. This gradual increase helps the body adjust to the medication, reducing the likelihood of severe side effects.

Routine Monitoring During Therapy

During Venclexta (Venetoclax) therapy, routine monitoring is essential to ensure patient safety and treatment effectiveness. Blood tests are regularly conducted to monitor white blood cell counts, liver and kidney function, and signs of tumor lysis syndrome (TLS). Patients may also undergo imaging scans to track tumor progression or response. Close observation helps adjust the dosage if necessary and manage any emerging side effects.

Tips for Maintaining a Healthy Lifestyle

Maintaining a healthy lifestyle during Venclexta (Venetoclax) treatment involves balancing diet, exercise, and mental well-being. It’s important to eat a balanced diet rich in fruits, vegetables, lean proteins, and whole grains to support the immune system. Staying hydrated is crucial to help flush out toxins and maintain kidney function. Gentle exercises, like walking or yoga, can help preserve strength and energy levels. Prioritize sleep, as rest is vital for healing and recovery. Additionally, managing stress through mindfulness, meditation, or connecting with loved ones can improve overall well-being. Regular check-ups with your healthcare team are also key to ensuring safe treatment progress.

What to Avoid During Venetoclax Treatment?

During   treatment, it’s important to take precautions to maximize the medication’s effectiveness and minimize potential side effects. Being aware of certain activities, substances, and environmental factors can help optimize your treatment experience.

Written by Sergey Badalyan